WO2005021513A1 - Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases - Google Patents
Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases Download PDFInfo
- Publication number
- WO2005021513A1 WO2005021513A1 PCT/SE2004/001227 SE2004001227W WO2005021513A1 WO 2005021513 A1 WO2005021513 A1 WO 2005021513A1 SE 2004001227 W SE2004001227 W SE 2004001227W WO 2005021513 A1 WO2005021513 A1 WO 2005021513A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- compound
- benzenesulfonamide
- dichloro
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
- C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
- C07D241/40—Benzopyrazines
- C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Virology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/570,178 US20070093491A1 (en) | 2003-08-27 | 2004-08-25 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases |
JP2006524604A JP2007503432A (en) | 2003-08-27 | 2004-08-25 | Novel fused N-pyrazinyl-sulfonamides and their use in the treatment of chemokine mediated diseases |
EP04775333A EP1660461B1 (en) | 2003-08-27 | 2004-08-25 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases |
DE602004017332T DE602004017332D1 (en) | 2003-08-27 | 2004-08-25 | NEW CONDENSED N-PYRAZINYL-SULFONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKIN-MEDIATED DISEASES |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0302304A SE0302304D0 (en) | 2003-08-27 | 2003-08-27 | Novel compounds |
SE0302304-1 | 2003-08-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005021513A1 true WO2005021513A1 (en) | 2005-03-10 |
Family
ID=28673200
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/SE2004/001227 WO2005021513A1 (en) | 2003-08-27 | 2004-08-25 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070093491A1 (en) |
EP (1) | EP1660461B1 (en) |
JP (1) | JP2007503432A (en) |
AT (1) | ATE411984T1 (en) |
DE (1) | DE602004017332D1 (en) |
ES (1) | ES2314445T3 (en) |
SE (1) | SE0302304D0 (en) |
WO (1) | WO2005021513A1 (en) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1661889A1 (en) * | 2003-09-05 | 2006-05-31 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
WO2007069978A1 (en) * | 2005-12-12 | 2007-06-21 | Astrazeneca Ab | Novel n-(fluoro-pyrazinyl)-phenylsulfonamid.es as moodulators of chemokine receptor ccr4. |
WO2007044729A3 (en) * | 2005-10-07 | 2007-08-09 | Exelixis Inc | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
WO2008101979A1 (en) * | 2007-02-22 | 2008-08-28 | Merck Serono S.A. | Quinoxaline compounds and use thereof |
US7662825B2 (en) | 2002-01-16 | 2010-02-16 | Astrazeneca Ab | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
WO2010053182A1 (en) | 2008-11-10 | 2010-05-14 | 協和発酵キリン株式会社 | Kynurenine production inhibitor |
WO2011142316A1 (en) | 2010-05-10 | 2011-11-17 | 協和発酵キリン株式会社 | Nitrogen-containing heterocyclic compound having kynurenine production inhibitory activity |
WO2012052420A1 (en) | 2010-10-20 | 2012-04-26 | Merck Serono S.A. Geneva | Method for preparing substituted n-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates n-(3-chloro-quinoxalin-2-yl)sulfonamides |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
WO2013069765A1 (en) | 2011-11-09 | 2013-05-16 | 協和発酵キリン株式会社 | Nitrogenated heterocyclic compound |
US8937068B2 (en) | 2005-11-11 | 2015-01-20 | Zentaris Gmbh | Pyridopyrazine derivatives and their use |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007063935A1 (en) * | 2005-12-02 | 2007-06-07 | Mitsubishi Tanabe Pharma Corporation | Aromatic compound |
US20090182140A1 (en) * | 2005-12-02 | 2009-07-16 | Mitsubishi Tanabe Pharma Corporation | Alicyclic Heterocyclic Compound |
US7940543B2 (en) * | 2008-03-19 | 2011-05-10 | Nanya Technology Corp. | Low power synchronous memory command address scheme |
WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
KR101102377B1 (en) * | 2011-11-11 | 2012-01-05 | 주식회사 에네스코 | Ultrasonic wave scanner for turbine rotor |
WO2024048615A1 (en) * | 2022-08-30 | 2024-03-07 | 協和キリン株式会社 | Method for producing quinoxaline derivative |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0215200A2 (en) * | 1985-06-24 | 1987-03-25 | Merck & Co. Inc. | Use of sulfanilamido quinoxalines in the treatment of neoplastic diseases |
EP0672662A1 (en) * | 1994-03-04 | 1995-09-20 | Eli Lilly And Company | Quinoxaline derivative used in the treatment of tumours |
WO1997032858A1 (en) * | 1996-03-05 | 1997-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives as glutamate receptor antagonists |
WO2003051870A1 (en) * | 2001-12-18 | 2003-06-26 | Astrazeneca Ab | Novel compounds |
WO2003059893A1 (en) * | 2002-01-16 | 2003-07-24 | Astrazeneca Ab | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
WO2004007472A1 (en) * | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1135471B (en) * | 1960-07-30 | 1962-08-30 | Basf Ag | Process for the preparation of 3-chloroquinoxaline derivatives |
BE611822A (en) * | 1960-12-21 | |||
FR1495549A (en) * | 1966-08-08 | 1967-12-20 | ||
CS156880B1 (en) * | 1972-02-09 | 1974-08-23 |
-
2003
- 2003-08-27 SE SE0302304A patent/SE0302304D0/en unknown
-
2004
- 2004-08-25 EP EP04775333A patent/EP1660461B1/en not_active Not-in-force
- 2004-08-25 JP JP2006524604A patent/JP2007503432A/en active Pending
- 2004-08-25 AT AT04775333T patent/ATE411984T1/en not_active IP Right Cessation
- 2004-08-25 US US10/570,178 patent/US20070093491A1/en not_active Abandoned
- 2004-08-25 WO PCT/SE2004/001227 patent/WO2005021513A1/en active Application Filing
- 2004-08-25 DE DE602004017332T patent/DE602004017332D1/en not_active Expired - Fee Related
- 2004-08-25 ES ES04775333T patent/ES2314445T3/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0215200A2 (en) * | 1985-06-24 | 1987-03-25 | Merck & Co. Inc. | Use of sulfanilamido quinoxalines in the treatment of neoplastic diseases |
EP0672662A1 (en) * | 1994-03-04 | 1995-09-20 | Eli Lilly And Company | Quinoxaline derivative used in the treatment of tumours |
WO1997032858A1 (en) * | 1996-03-05 | 1997-09-12 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives as glutamate receptor antagonists |
WO2003051870A1 (en) * | 2001-12-18 | 2003-06-26 | Astrazeneca Ab | Novel compounds |
WO2003059893A1 (en) * | 2002-01-16 | 2003-07-24 | Astrazeneca Ab | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
WO2004007472A1 (en) * | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
Non-Patent Citations (1)
Title |
---|
DATABASE CAPLUS [online] "Preparation of pyrazine and quinoxaline derivatives as chemokine receptor CCR4 antagonists and medicinal use thereof", XP002903885, accession no. STN Database accession no. 2004:60488 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7662825B2 (en) | 2002-01-16 | 2010-02-16 | Astrazeneca Ab | N-pyrazinyl-phenylsulphonamides and their use in the treatment of chemokine mediated diseases |
US7732442B2 (en) | 2003-09-05 | 2010-06-08 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
EP1661889A4 (en) * | 2003-09-05 | 2009-08-05 | Ono Pharmaceutical Co | Chemokine receptor antagonist and medical use thereof |
EP1661889A1 (en) * | 2003-09-05 | 2006-05-31 | Ono Pharmaceutical Co., Ltd. | Chemokine receptor antagonist and medical use thereof |
CN103819416A (en) * | 2005-10-07 | 2014-05-28 | 埃克塞里艾克西斯公司 | N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
NO341737B1 (en) * | 2005-10-07 | 2018-01-15 | Exelixis Inc | N- (3-amino-quinoxaline-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol kinase inhibitors |
KR101396783B1 (en) | 2005-10-07 | 2014-05-21 | 엑셀리시스, 인코포레이티드 | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
EA024305B1 (en) * | 2005-10-07 | 2016-09-30 | Экселиксис, Инк. | Phosphatidylinositol 3-kinase inhibitors and use thereof |
WO2007044729A3 (en) * | 2005-10-07 | 2007-08-09 | Exelixis Inc | N- (3-amino-quinoxalin-2-yl) -sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors |
US7989622B2 (en) | 2005-10-07 | 2011-08-02 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
EP2364974A1 (en) * | 2005-10-07 | 2011-09-14 | Exelixis, Inc. | N-(3-Phenylamino-quinoxalin-2-yl)-benzenesulfonamide derivatives as phosphatidylinositol 3-kinase inhibitors |
EA019255B1 (en) * | 2005-10-07 | 2014-02-28 | Экселиксис, Инк. | Phosphatidylinositol 3-kinase inhibitors and pharmaceutical compositions containing them |
US8889664B2 (en) | 2005-10-07 | 2014-11-18 | Exelixis, Inc. | Phosphatidylinositol 3-kinase inhibitors and methods of their use |
US8937068B2 (en) | 2005-11-11 | 2015-01-20 | Zentaris Gmbh | Pyridopyrazine derivatives and their use |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
WO2007069978A1 (en) * | 2005-12-12 | 2007-06-21 | Astrazeneca Ab | Novel n-(fluoro-pyrazinyl)-phenylsulfonamid.es as moodulators of chemokine receptor ccr4. |
JP2010519244A (en) * | 2007-02-22 | 2010-06-03 | メルク セローノ ソシエテ アノニム | Quinoxaline compounds and uses thereof |
CN101663283B (en) * | 2007-02-22 | 2014-04-09 | 默克雪兰诺有限公司 | Quinoxaline compounds and use thereof |
WO2008101979A1 (en) * | 2007-02-22 | 2008-08-28 | Merck Serono S.A. | Quinoxaline compounds and use thereof |
US8614215B2 (en) | 2007-02-22 | 2013-12-24 | Merck Serono Sa | Quinoxaline inhibitors of phosphoinositide-3-kinases (PI3Ks) |
JP5687903B2 (en) * | 2008-11-10 | 2015-03-25 | 協和発酵キリン株式会社 | Kinurenin production inhibitor |
US8673908B2 (en) | 2008-11-10 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd. | Kynurenine production inhibitor |
WO2010053182A1 (en) | 2008-11-10 | 2010-05-14 | 協和発酵キリン株式会社 | Kynurenine production inhibitor |
US9150569B2 (en) | 2010-05-10 | 2015-10-06 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine |
WO2011142316A1 (en) | 2010-05-10 | 2011-11-17 | 協和発酵キリン株式会社 | Nitrogen-containing heterocyclic compound having kynurenine production inhibitory activity |
US10548891B2 (en) | 2010-05-10 | 2020-02-04 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine |
WO2012052420A1 (en) | 2010-10-20 | 2012-04-26 | Merck Serono S.A. Geneva | Method for preparing substituted n-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates n-(3-chloro-quinoxalin-2-yl)sulfonamides |
CN103270027A (en) * | 2010-10-20 | 2013-08-28 | 默克雪兰诺日内瓦有限公司 | Method for preparing substituted n-3-amino-quinoxalin-<wbr/>2-yl)-sulfonamides and their intermediates n-<wbr/>(3-chloro-quinoxalin-<wbr/>2-yl)sulfonamides |
US9067923B2 (en) | 2011-11-09 | 2015-06-30 | Kyowa Hakko Kirin Co., Ltd. | Substituted quinoxalines |
WO2013069765A1 (en) | 2011-11-09 | 2013-05-16 | 協和発酵キリン株式会社 | Nitrogenated heterocyclic compound |
EP3312173A1 (en) | 2011-11-09 | 2018-04-25 | Kyowa Hakko Kirin Co., Ltd. | Nitrogen-containing heterocyclic compound |
Also Published As
Publication number | Publication date |
---|---|
SE0302304D0 (en) | 2003-08-27 |
ATE411984T1 (en) | 2008-11-15 |
US20070093491A1 (en) | 2007-04-26 |
JP2007503432A (en) | 2007-02-22 |
EP1660461A1 (en) | 2006-05-31 |
DE602004017332D1 (en) | 2008-12-04 |
ES2314445T3 (en) | 2009-03-16 |
EP1660461B1 (en) | 2008-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1633729B1 (en) | Sulphonamide compounds that modulate chemokine receptor activity (ccr4) | |
EP1660461B1 (en) | Novel condensed n-pyrazinyl-sulphonamides and their use in the treatment of chemokine mediated diseases | |
EP1625127B1 (en) | Azaindole compounds as kinase inhibitors | |
US20080306262A1 (en) | Novel Compound | |
ZA200502267B (en) | Novel compound. | |
US20060128723A1 (en) | Sulptionamide compounds that modulate chemokine receptor activity (CCR4) | |
US20060189613A1 (en) | Sulphonamide Compounds that Modulate Chemokine Receptor Activity (CCR4) | |
US20110053969A1 (en) | Novel diazasipiroakanes and their use for treatment of ccr8 mediated diseases | |
CA2730477A1 (en) | Pyrimidyl sulfonaminde derivative and its use for the treatment of chemokine mediated diseases | |
US20090118318A1 (en) | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases | |
US20090215807A1 (en) | Novel Diazaspiroalkanes and Their Use for Treatment of CCR8 Mediated Diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004775333 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007093491 Country of ref document: US Ref document number: 10570178 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006524604 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004775333 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10570178 Country of ref document: US |